Cargando…
Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia
Background: Acute myeloid leukemia (AML) is a malignant hematological disease with high refractory rate. Immune escape of AML cells is one of the underlying mechanisms mediating the relapse of the cancers. Various immunotherapies based on the 'patients' immune response to tumor cells have...
Autores principales: | Zhong, Guocheng, Jin, Guangyi, Zeng, Wei, Yu, Changhua, Li, Yan, Zhou, Ji, Zhang, Li, Yu, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484644/ https://www.ncbi.nlm.nih.gov/pubmed/32922200 http://dx.doi.org/10.7150/ijms.49983 |
Ejemplares similares
-
MAGEA1 and hTERT Peptide Treatment Improves the Potency of The Dendritic Cell- Cytotoxic T Lymphocytes (DC-CTL) Immunotherapy in DAC Treated Acute Myeloid Leukemia
por: Zhong, Guocheng, et al.
Publicado: (2022) -
A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist
por: Chi, Huju, et al.
Publicado: (2022) -
High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation
por: Gadd, Adam J.R., et al.
Publicado: (2018) -
Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity
por: Ren, Sumei, et al.
Publicado: (2022) -
Demethylator phenotypes in acute myeloid leukemia
por: Kelly, Andrew D., et al.
Publicado: (2018)